Finasteride capsules

This product belongs to the 4-nitrogen steroid hormone compound, which is a specific type II 5α-reductase competitive inhibitor. It inhibits the conversion of peripheral testosterone into dihydrotestosterone and reduces the level of dihydrotestosterone in the blood, prostate, skin and other tissues. The growth, development and benign hyperplasia of the prostate depend on dihydrotestosterone. Finasteride inhibits prostate hyperplasia and improves the related clinical symptoms of benign prostatic hyperplasia by reducing the level of dihydrotestosterone in the blood and prostate tissue.

Molecular weight: C23H36N2O2

This product is a special-shaped film-coated tablet, which appears white or off-white after removing the coating.

This product is suitable for the treatment of symptomatic benign prostatic hyperplasia (BPH). ————Improve symptoms; ————Reduce the risk of acute urinary retention; ————Reduce the risk of transurethral resection of the prostate (TURP) and prostatectomy.

Oral. Recommended dose: 5 mg (1 tablet) once a day, either on an empty stomach or with food.

Well tolerated. The most common adverse effects are impotence and reduced ejaculation volume. Occasionally, breast enlargement and tenderness, allergic reactions, etc.

1. Those who are allergic to any component of this product. 2. Women and children are prohibited from using this product.

Precautions for children: This product is not suitable for children. Safety and efficacy data for children have not been determined. Precautions for pregnancy and lactation: This product is contraindicated for women who are pregnant or may become pregnant. Since type II 5a-reductase inhibitors, including finasteride, inhibit the conversion of testosterone to dihydrotestosterone, when taken by pregnant women, it can cause abnormalities in the external genitalia of male fetuses. Women who are pregnant or may become pregnant should not come into contact with fragments and splinters of this product. This product is not suitable for breastfeeding women. It is not known whether finasteride is excreted in human milk. Precautions for the elderly: Elderly patients do not need to adjust the dosage.

1. Finasteride has no significant effect on the cytochrome P450-related drug metabolizing enzyme system. Compounds that have been tested in men include propranolol, digoxin, glibenclamide, warfarin, theophylline and antipyrine, and no clinically significant interactions with finasteride have been found. 2. Other combined therapies. Although no specific drug interaction studies have been conducted, in clinical studies, no significant clinical interactions were found when finasteride was used simultaneously with angiotensin-converting enzyme inhibitors, acetaminophen, acetylsalicylic acid, alpha-blockers, beta-blockers, calcium channel blockers, nitrates for heart disease, diuretics, H2 receptor antagonists, HMG-CoA reductase inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), quinolones and benzodiazepines.

Sealed and protected from light.

5mg

36 months

Jiangsu Xiangrui Pharmaceutical Co., Ltd.

• Founded in:

  2003-12-18

• Address:

  Xiangshui County West (inside the former pharmaceutical factory)

• Tax NO.:

  91320921757309253K

• Registered Funds:

  20 million yuan

• Email:

  Log in to view